After-hours trading shows InflaRx NV (IFRX) shares up 39.51% at $3.99. IFRX shares closed unchanged at $2.86 in regular session. The stock price of IFRX fluctuated between $2.78 and $3.00 throughout the day. During the trading period, IFRX stock exchanged 1.07 million shares, which was more than the company’s 50-day daily volume of 0.78 million and higher than its year-to-date volume of 0.42 million shares.
IFRX stock has lost -32.39% over the last year, and in the last week, the stock has risen 3.62%. IFRX stock has lost -23.53% over the last six months, and over the last three months, the stock has increased by 10.42%. The stock has lost -43.14% since the beginning of 2018. IFRX stock surged following positive clinical trial results.
What trials has IFRX conducted?
InflaRx is a clinical-stage biopharmaceutical organization focused on applying its proprietary anti-C5a innovation to find and foster first-in-class, strong and explicit inhibitors of C5a. Supplement C5a is an incredible inflammatory mediator associated with the movement of a wide assortment of immune system and other provocative illnesses. IFRX was established in 2007, and has workplaces and auxiliaries in Jena and Munich, Germany, just as Ann Arbor, MI, USA.
The third cohort of patients in InflaRx’s Phase IIa open-label study of vilobelimab in Pyoderma Gangrenosum (PG) has reported positive results.
- In the proof-of-concept study, 19 patients were selected by IFRX, with seven patients participating in the third cohort.
- Patients were treated by IFRX for 26 weeks with vilobelimab 800mg, 1600mg or 2400mg fortnightly, after a run-in phase of three doses of 800mg on days 1, 4 and 8.
- For the third cohort, patients were observed for two months following the treatment period.
- On day 57 of treatment, patients were able to receive a dose increase to the next higher dosing group if five or more patients in the cohort were free of safety concerns and the patient had a Physician Global Assessment (PGA) score of 4 or higher.
- Clinical remission was achieved in six of the seven patients with PGA scores of ≤1, indicating closure of the target ulcer.
- Vilobelimab consistently suppressed C5a levels in all cohort 3 patients after initiation of treatment.
Overview of IFRX’s study:
InflaRx (IFRX)’s study on vilobelimab for people with PG has two main objectives: testing its safety and efficacy. At various timepoints and until the target ulcer is completely closed, the efficacy of the treatment is assessed by the PGA score of ≤3.